OHSU Knight Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OHSU Knight Cancer Institute sits in the top decile of US sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count).
OHSU Knight Cancer Institute: 211 sponsored US clinical trials, 35 recruiting.
OHSU Knight Cancer Institute sponsors 211 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 94 completed. 5 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 6 trials.
Top-decile sponsor footprint
OHSU Knight Cancer Institute ranks in the top decile of sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
94 of 149 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
211 total, page 5 of 5
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
NCT00031811
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00017576
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
NCT00017563
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
NCT00659334
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00074191
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00074178
Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer
NCT00217724
Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer
NCT00004043
Docetaxel in Treating Patients With Stage IV Prostate Cancer
NCT00003781
Melphalan With BBBD in Treating Patients With Brain Malignancies
NCT00253721
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
NCT00900055
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 73 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the OHSU Knight Cancer Institute pipeline
35 recruiting of 211 indexed (17% open); 94 completed (45%).
Phase mix: 5 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OHSU Knight Cancer Institute: open-pipeline peers nationwide
Peers matched on 211 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
OHSU Knight Cancer Institute sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 211 trials (± recruiting share)
- MedImmune · 210 trials · 0% recruiting
- University of Louisville · 217 trials · 21% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- Massachusetts General Hospital · 17% recruiting · 2,032 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this OHSU Knight Cancer Institute page
211 registered trials is a research-attention snapshot, not an endorsement of OHSU Knight Cancer Institute or any single study.
- 35 of OHSU Knight Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition OHSU Knight Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OHSU Knight Cancer Institute pipeline card: 211 registered trials from official public datasets.Report a data error.